Hikma is introducing mercaptopurine oral suspension, in a 20mg/ml dose, which is the first generic of this product. Hikma was the first approved applicant with a Competitive Generic Therapy ...

Shares of Hikma Pharmaceuticals stock opened at GBX 2,123.65 ($27.45) on Friday. The stock has a market capitalization of £5.89 billion, a P/E ratio of 20.84, a PEG ratio of 2.38 and a beta of 0.41.

Axsome Therapeutics has entered into a settlement agreement with Hikma resolving patent litigation related to Axsome’s product Sunosi (solriamfetol). The litigation, which is pending in the ...

Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to patents for its narcolepsy drug, Sunosi (solriamfetol). The settlement ...

Hikma Pharmaceuticals (HKMPF) is in talks with partners across the world to prepare to sell a generic version of Ozempic and Wegovy, as patents on Novo Nordisk’s (NVO) diabetes and weight loss ...

In a report released today, James Gordon from J.P. Morgan maintained a Buy rating on Hikma Pharmaceuticals (HIK – Research Report), with a price target of p2,600.00. The company’s shares ...

Hikma Pharmaceuticals PLC posted 'robust' financial results for 2024, with revenue climbing 9 per cent to $3.127 billion (JT file) AMMAN — Hikma Pharmaceuticals PLC posted 'robust' financial results ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Drugmaker Hikma is in talks with partners across the world to prepare to sell a generic version of Ozempic ...

Group core revenue up 10%, including contribution from Xellia acquisition (9% organic). Reported Group revenue up 9% Core revenue up in all three business segments – Injectables up 10%, Branded up 8% ...

Revenue: US$3.13b (up 8.8% from FY 2023). Net income: US$359.0m (up 89% from FY 2023). Profit margin: 12% (up from 6.6% in FY 2023). The increase in margin was driven by higher revenue. EPS: US$1. ...

Investing.com -- Shares of Hikma Pharmaceuticals (LON:HIK) fell over 5% on Wednesday following its FY24 results, as core operating profits and weaker-than-expected margins failed to meet investor ...